2023
Multicenter Transthyretin Cardiac Amyloidosis Study Demonstrates Differences In Phenotype And Outcomes By Race
Cavalier J, Bhattacharya P, Patolia H, Chandramouli S, Sen S, Karra R, Maurer M, Khouri M. Multicenter Transthyretin Cardiac Amyloidosis Study Demonstrates Differences In Phenotype And Outcomes By Race. Journal Of Cardiac Failure 2023, 29: 699-700. DOI: 10.1016/j.cardfail.2022.10.381.Peer-Reviewed Original ResearchATTR-CM patientsReduced ejection fractionEjection fractionBlack patientsATTR-CMHeart failureWhite patientsAdvanced stageFindings merit further researchHigher NT-proBNP levelsMid-range ejection fractionNT-proBNP levelsNYHA class INYHA class IIILow ejection fractionRetrospective multicenter analysisTransthyretin amyloid cardiomyopathyLarge academic medical centerCross-sectional studyAcademic medical centerDeceased patientsMulticenter analysisWorsened prognosisRace patientsVital status
2021
Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, O’Connor C, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations Quality & Outcomes 2021, 5: 447-455. PMID: 33997640, PMCID: PMC8105522, DOI: 10.1016/j.mayocpiqo.2021.02.005.Peer-Reviewed Original ResearchNT-proBNP levelsReduced ejection fractionAtrial fibrillationHF hospitalizationHeart failureEjection fractionMedical therapyN-terminal pro-B-type natriuretic peptideOptimal guideline-directed medical therapyPro-B-type natriuretic peptideGuideline-directed medical therapyHigher NT-proBNP concentrationsHigher NT-proBNP levelsGUIDE-IT trialMedical therapy useHeart failure outcomesHeart Failure TrialPrevalent atrial fibrillationNT-proBNP concentrationsType natriuretic peptideEvidence-based therapiesCardiovascular deathAF patientsTherapy useFailure Trial